Skip to main content

. 1994 Jan;70(1):F78. doi: 10.1136/fn.70.1.f78

Adverse experiences in an Exosurf treated group.

S L Chatfield, E J Kelly, P R Dear

PMCID: PMC1060998 PMID: 8117137

F78

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Long W., Corbet A., Cotton R., Courtney S., McGuiness G., Walter D., Watts J., Smyth J., Bard H., Chernick V. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group. N Engl J Med. 1991 Dec 12;325(24):1696–1703. doi: 10.1056/NEJM199112123252404. [DOI] [PubMed] [Google Scholar]
Long W., Thompson T., Sundell H., Schumacher R., Volberg F., Guthrie R. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. The American Exosurf Neonatal Study Group I. J Pediatr. 1991 Apr;118(4 Pt 1):595–605. doi: 10.1016/s0022-3476(05)83388-8. [DOI] [PubMed] [Google Scholar]
Phibbs R. H., Ballard R. A., Clements J. A., Heilbron D. C., Phibbs C. S., Schlueter M. A., Sniderman S. H., Tooley W. H., Wakeley A. Initial clinical trial of EXOSURF, a protein-free synthetic surfactant, for the prophylaxis and early treatment of hyaline membrane disease. Pediatrics. 1991 Jul;88(1):1–9. [PubMed] [Google Scholar]

ACTIONS

RESOURCES